多原发非小细胞肺癌诊断、治疗及预后的系统性综述  

Diagnosis, treatment and prognosis of patients with multiple primary non-small cell lung cancer:A systematic review

作　　者：刘毅[1] 初向阳[1] 

机构地区：[1]解放军总医院胸外科,北京100853

出　　处：《解放军医学院学报》2016年第8期901-904,911,共5页Academic Journal of Chinese PLA Medical School

基　　金：北京市自然科学基金项目(7142152)~~

摘　　要：近年来,由于诊断和检查手段的改进及人口老龄化加剧,多原发肺癌（multiple primary lung cancer,MPLC）的发病率在世界范围内呈持续性增长趋势。MPLC包括同时性多原发肺癌（synchronous multiple primary lung cancers,s MPLC）及异时性多原发肺癌（metachronous multiple primary lung cancers,m MPLC）。非小细胞肺癌（non-small cell lung cancer,NSCLC）中,有0.2%～8%为MPLC。MPLC与肺内转移癌（intrapulmonary metastases,IM）的鉴别比较困难,主要通过病理结果分析进行鉴别。基因检测可在一定程度上鉴别IM和MPLC。手术切除和立体定性放疗被认为是治疗MPLC的有效方法。MPLC的预后优于IM,其生存期由最高分期的肿瘤决定。The incidence of multiple primary lung cancers（MPLC）, including synchronous multiple primary lung cancers（s MPLC） and metachronous multiple primary lung cancers（m MPLC）, has been increasing in recent years due to the development of screenning, early detection techniques and the ageing population. A substantial percentage（0.2%-8%） of all newly diagnosed nonsmall cell lung cancer（NSCLC） cases are MPLCs. The distinction between multiple primary lung cancers and intrapulmonary metastases（IM） is based on pathological criteria, however, it is very difficult. Newly developed genetic methods are believed to be helpful for the distinction between MPLC and IM. Surgical treatment and stereotactic body radiation therapy are considered as effective methods in treating MPLC. Surgery options are varies from person to person due to different conditions of each patient. The prognosis of patients with MPLC, depended on the highest TNM stage tumor, is better than patients with IM.

关 键 词：同时性多原发肺癌 异时性多原发肺癌 诊断 治疗 预后 

分 类 号：R734.2[医药卫生—肿瘤]